Emergent Biosolutions Inc (EBS)
R&D to Revenue
3.93%
Quarterly · Period ending:
EBS R&D to Revenue
Latest reported3.93%period ending
Latest reported3.93%period ending
EBS Quarterly R&D/Revenue (17.42% → 3.93%)
Latest values, visible window
High-resolution chart · PNG
EBS r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 3.9266% | |
| 6.7265% | |
| 8.1372% | |
| 5.8416% | |
| 9.2264% | |
| 6.8407% | |
| 4.6739% | |
| 4.6971% | |
| 12.8386% | |
| 5.0266% | |
| 10.6291% | |
| 5.6562% | |
| 7.6946% | |
| 24.7718% | |
| 14.2338% | |
| 17.5907% | |
| 21.9675% | |
| 15.0894% | |
| 11.4768% | |
| 15.076% | |
| 12.3019% | |
| 15.3061% | |
| 10.2058% | |
| 21.9107% | |
| 12.1358% | |
| 22.1818% | |
| 18.6794% | |
| 17.1264% | |
| 26.2747% | |
| 24.1868% | |
| 19.2095% | |
| 21.3134% | |
| 11.2171% | |
| 24.7029% | |
| 14.7104% | |
| 15.1632% | |
| 25.5537% | |
| 17.5221% | |
| 17.8798% | |
| 19.024% | |
| 30.5707% | |
| 25.3419% | |
| 15.867% | |
| 21.5806% | |
| 19.4837% | |
| 60.8206% | |
| 25.9943% | |
| 32.4072% | |
| 33.9007% | |
| 56.1502% | |
| 30.5727% | |
| 32.4763% | |
| 36.7291% | |
| 71.2854% | |
| 37.9944% | |
| 41.1311% | |
| 43.5428% | |
| 52.1675% | |
| 27.2131% | |
| 49.7192% | |
| 35.7166% | |
| 187.5519% | |
| 28.6836% | |
| 28.5946% | |
| 29.9366% | |
| 42.5684% | |
| 35.7334% | |
| 43.3814% | |
| 28.2548% | |
| 24.6594% | |
| 39.614% | |
| 29.3768% | |
| 39.5677% | |
| 26.861% | |
| 13.6874% | |
| 29.2755% | |
| 57.5433% | |
| 58.8702% | |
| 21.707% | |
| 40.4593% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 17.4176% | |
| 15.076% | |
| 7.6946% | |
| 15.0894% | |
| 17.4176% |